Results 131 to 140 of about 10,498 (275)

Over-expression of a specific soybean GmGSTU4 isoenzyme improves chloroacetanilide herbicide tolerance of transgenic tobacco plants [PDF]

, 2015
Plant glutathione transferases (GSTs) have a major role in herbicide detoxification. Soybean (Glycine max L.) GmGSTs have been well studied for their correlation in herbicides selectivity towards diphenyl ether, chloroacetanilide and sulfonylurea ...
AthanasiosTsaftaris,, Benekos, Kostantinos, Kissoudis, Christos, Labrou, Nikolaos E., Madesis, Panagiotis, Nianiou-Obeidat, Irini, Voulgari, Georgia   +6 more
core  

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 972-981, February 2026.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

Synthesis and Herbicidal Activity of Sulfonylurea Compounds with Imidazo [1, 2-<i>a</i>] pyridine Moiety

, 2001
Shigeyuki Itoh, Kazunari OHTA, Takahiro Yamawaki, Yasuo Ishida   +3 more
openalex   +2 more sources

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley, Christopher T. Rentsch, Elizabeth Williamson, Anoop S. V. Shah, Patrick Bidulka, Charlotte Warren‐Gash, Marleen Bokern, Rohini Mathur   +7 more
wiley   +1 more source

Sensitivity of a renal K+ channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamide is enhanced by coexpression with the ATP-binding cassette transporter cystic fibrosis transmembrane regulator.

, 1996
Carmel M. McNicholas, William B. Guggino, Erik M. Schwiebert, S. C. Hebert, Gerhard Giebisch, Marie E. Egan   +5 more
openalex   +2 more sources

Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation

, 2022
Changwen Zhang, Ayyiliath M. Sajith, Xiaotian Xu, Jianxiong Jiang, J. Phillip Bowen, Amol A. Kulkarni, Jiukuan Hao   +6 more
openalex   +2 more sources

Acute toxicity of novel N-sulfonylpyrimidine derivatives in vivo [PDF]

The aim of the present study was to investigate in vivo toxic effects and to find acute toxic doses (LD 50) of novel N-sulfonyl derivatives of pyrimidine nucleobases uracil and cytosine. Six N-1-sulfonyluracil derivatives (1, 2, 6, 7, 8, and 9) and two N-
Biserka Žinić, Jure Jerčić, Ksenija Vlahović, Marina Pavlak, Marko Radačić, Ranko Stojković   +5 more
core  

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1247-1257, February 2026.
Abstract Aims Cancer diagnosis may increase the risk of developing prediabetes/diabetes and subsequently worsen survival in cancer patients. However, it is unclear whether this association is influenced by the timing of hyperglycemia onset or the use of antihyperglycemic medications.
Maci Winn, Svenja Pauleck, Stephanie Richardson, Richard Viskochil, Prasoona Karra, Howard Colman, Jennifer A. Doherty, Yizhe Xu, Siwen Hu‐Lieskovan, Michelle Litchman, Mary C. Playdon, Sheetal Hardikar   +11 more
wiley   +1 more source

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi, Nader Albalkhi, Ibrahim Al Kadhim, Ahmed Elsadig, Dimitrios Baltzis, Mohamed Hassan Hatahet, Mahmoud Ismail, Said Khader, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Ahmed Shalaby, Mohammed Almehthel   +11 more
wiley   +1 more source